Keywords: powderject, gsk, dna, vaccine, shows, promise, hbv
PowderJect, GSK DNA vaccine shows promise in HBV
Article | 25 April 2001
PowderJect Pharmaceuticals and its subsidiary PowderJect Vaccines haveannounced that a DNA vaccine, produced in collaboration with GlaxoSmithKline, has provided 80% of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
